Hepatotoxicity of antimicrobials and antifungal agents

Drug-Induced Liver Disease

Volumn , Issue , 2013, Pages 463-481

  Moseley, Richard H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Amoxicillin clavulanic acid; Azole agents; Drug induced autoimmune hepatitis; Flucloxacillin; Minocycline; Nitrofurantoin; Terbinafine; Trimethoprim sulfamethoxazole; Trovafloxacin

Indexed keywords

EID: 84882582808     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387817-5.00026-1     Document Type: Chapter

References (316)

1. Chand N., Sanyal A.J. Sepsis-induced cholestasis. Hepatology 2007, 45:230-241.
2. Kosters A., Karpen S.J. The role of inflammation in cholestasis: clinical and basic aspects. Semin Liver Dis 2010, 30:186-194.
3. Carson J.L., Brian L., Strom B.L., Duff A., Gupta A., Shaw M., et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993, 119:576-583.
4. Sgro C., Clinard F., Ouazir K., Chanay H., Allard C., Guilleminet C., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36:451-455.
5. de Abajo F.J., Montero D., Madurga M., Garcia Rodriguez L.A. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004, 58:71-80.
6. Galan M.V., Potts J.A., Silverman A.L., Gordon S.C. Hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005, 39:64-67.
7. Meier Y., Cavallaro M., Roos M., Pauli-Magnus C., Folkers G., Meier P.J., et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005, 61:135-143.
8. Andrade R.J., Lucena M.I., Fernandez M.C., Pelaez G., Pachkoria K., García-Ruiz E.L., Spanish Group for the Study of Drug-Induced Liver Disease, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512-521.
9. Sabaté M., Ibáñez L., Pérez E., Vidal X., Buti M., Xiol X., et al. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther 2007, 25:1401-1409.
10. De Valle M.B., Klinteberg AV V., Alem N., Olsson R., Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006, 24:1187-1195.
11. Bjornsson E., Jerlstad P., Bergqvist A., Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005, 40:1095-1101.
12. Bjornsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005, 42:481-489.
13. Chalasani N., Fontana R.J., Bonkovsky H.L., Watkins P.B., Davern T., Serrano J., Drug Induced Liver Injury Network (DILIN), et al. Causes, clinical features, and outcomes, from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934.
14. Reuben A., Koch D.G., Lee W.M. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010, 52:2065-2076.
15. Björnsson E., Talwalkar J., Treeprasertsuk S., Kamath P.S., Takahashi N., Sanderson S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010, 51:2040-2048.
16. Czaja A.J. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011, 56:958-976.
17. Parry M.F. The pencillins. Med Clin North Am 1987, 71:1093-1112.
18. Goldstein L.I., Ishak K.G. Hepatic injury associated with penicillin therapy. Arch Pathol 1974, 98:114-117.
19. Williams C.N., Malatjalian D.A. Severe penicillin-induced cholestasis in a 91-year-old woman. Dig Dis Sci 1981, 26:470-473.
20. Onate J., Montejo M., Aguirrebengoa K., Ruiz-Irastorza G., Gonzalez de Zarate P., Aguirre C. Hepatotoxicity associated with penicillin V therapy. Clin Infect Dis 1995, 20:474-475.
21. Andrade R.J., Guilarte J., Salmeron F.J., Lucena M.I., Bellot V. Benzylpenicillin-induced prolonged cholestasis. Ann Pharmacother 2001, 35:783-784.
22. Cavanzo F.J., Garcia C.F., Botero R.C. Chronic cholestasis, paucity of bile ducts, red cell aplasia, and the Stevens-Johnson syndrome: an ampicillin-associated case. Gastroenterology 1990, 99:854-856.
23. Koklu S., Yuksel O., Filik L., Uskudar O., Altundag K., Altiparmak E. Recurrent cholestasis due to ampicillin. Ann Pharmacother 2003, 37:395-397.
24. Koklu S., Koksal A.S., Asil M., Kiyici H., Coban S., Arhan M. Probable sulbactam/ampicillin-associated prolonged cholestasis. Ann Pharmacother 2004, 38:2055-2058.
25. Garcia Rodriguez L.A., Stricker B.H., Zimmerman H.J. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996, 156:1327-1332.
26. Davies M.H., Harrison R.F., Elias E., Hubscher S.G. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol 1994, 20:112-116.
27. Miller W.I., Souney P.F., Chang J.T. Hepatic dysfunction following nafcillin and cephalothin therapy in a patient with a history of oxacillin hepatitis. Clin Pharm 1983, 2:465-468.
28. Mazuryk H., Kastenberg D., Rubin R., Munoz S.J. Cholestatic hepatitis associated with the use of nafcillin. Am J Gastroenterol 1993, 88:1960-1962.
29. Schuman R., Miskovitz P. Nafcillin-associated jaundice. Am J Gastroenterol 1994, 89:952.
30. Presti M.E., Janney C.G., Neuschwander-Tetri B.A. Nafcillin-associated hepatotoxicity: report of a case and review of the literature. Dig Dis Sci 1996, 41:180-184.
31. Wilson F.M., Belamaric J., Lauter C.B., Lerner A.M. Anicteric carbenicillin hepatitis. Eight episodes in four patients. JAMA 1975, 232:818-821.
32. Siegmund J.B., Tarshis A.M. Prolonged jaundice after dicloxacillin therapy. Am J Gastroenterol 1993, 88:1299-1300.
33. Kleinman M.S., Presberg J.E. Cholestatic hepatitis after dicloxacillin-sodium therapy. J Clin Gastroenterol 1986, 8:77-78.
34. Saab S., Venkataramani A., Yao F. Possible granulomatous hepatitis after dicloxacillin therapy. J Clin Gastroenterol 1996, 22:163-164.
35. Olsson R., Wiholm B.E., Sand C., Zettergren L., Hultcrantz R., Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992, 15:154-161.
36. Konikoff F., Alcalay J., Halevy J. Cloxacillin-induced cholestatic jaundice. Am J Gastroenterol 1986, 81:1082-1083.
37. Pascual J., Orofino L., Marcen R., Quereda C., Ortuno J. Cloxacillin-induced cholestasis in a renal allograft patient with chronic hepatitis. Am J Gastroenterol 1990, 85:335-336.
38. Lotric S., Lejko-Zupanc T., Jereb M. Cloxacillin-induced cholestasis. Clin Infect Dis 1994, 19:981-982.
39. Goland S., Malnick S.D., Gratz R., Feldberg E., Geltner D., Sthoeger Z.M. Severe cholestatic hepatitis following cloxacillin treatment. Postgrad Med J 1998, 74:59-60.
40. Klein I., Tobias H. Oxacillin-associated hepatitis. Am J Gastroenterol 1976, 65:546.
41. Pollock A.A., Berger S.A., Simberkoff M.S., Rahal J.J. Hepatitis associated with high-dose oxacillin therapy. Arch Intern Med 1978, 138:915-917.
42. Onorato I.M., Axelrod J.L. Hepatitis from intravenous high-dose oxacillin therapy: findings in an adult inpatient population. Ann Intern Med 1978, 89:497-500.
43. Bruckstein A.H., Attia A.A. Oxacillin hepatitis. Two patients with liver biopsy, and review of the literature. Am J Med 1978, 64:519-522.
44. Goldstein L.I., Granoff M., Waisman J. Hepatic injury due to oxacillin administration. Am J Gastroenterol 1978, 70:171-174.
45. Halloran T.J., Clague M.D. Hepatitis associated with high-dose oxacillin therapy. Arch Intern Med 1979, 139:376-377.
46. D'Angelo L.J. Oxacillin and hepatotoxicity. Ann Intern Med 1979, 90:442.
47. Tauris P., Jorgensen N.F., Petersen C.M., Albertsen K. Prolonged severe cholestasis induced by oxacillin derivatives. A report on two cases. Acta Med Scand 1985, 217:567-569.
48. Al-Homaidhi H., Abdel-Haq N.M., El-Baba M., Asmar B.I. Severe hepatitis associated with oxacillin therapy. South Med J 2002, 95:650-652.
49. Maraqa N.F., Gomez M.M., Rathore M.H., Alvarez A.M. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. Clin Infect Dis 2002, 34:50-54.
50. Saliba B., Herbert P.N. Oxacillin hepatotoxicity in HIV-infected patients. Ann Intern Med 1994, 120:1048.
51. Aderka D., Livni E., Salamon F., Weinberger A., Pinkhas J. Use of macrophage inhibition factor and mast-cell degranulation tests for diagnosis of cloxacillin-induced cholestasis. Am J Gastroenterol 1986, 81:1084-1086.
52. Horikawa M., Kato Y., Tyson C.A., Sugiyama Y. Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet 2003, 18:16-22.
53. Wolf K.K., Vora S., Webster L.O., Generaux G.T., Polli J.W., Brouwer K.L. Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport. Toxicol in Vitro 2010, 24:297-309.
54. Lobatto S., Dijkmans B.A., Mattie H., Van Hooff J.P. Flucloxacillin-associated liver damage. Neth J Med 1982, 25:47-48.
55. Bengtsson F., Floren C.H., Hagerstrand I., Soderstrom C., Aberg T. Flucloxacillin-induced cholestatic liver damage. Scand J Infect Dis 1985, 17:125-128.
56. Turner I.B., Eckstein R.P., Riley J.W., Lunzer M.R. Prolonged hepatic cholestasis after flucloxacillin therapy. Med J Aust 1989, 151:701-705.
57. Fairley C.K., McNeil J.J., Desmond P., Smallwood R., Young H., Forbes A., et al. Risk factors for development of flucloxacillin associated jaundice. Br Med J 1993, 306:233-235.
58. Devereaux B.M., Crawford D.H., Purcell P., Powell L.W., Roeser H.P. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic?. Eur J Clin Pharmacol 1995, 49:81-85.
59. Piotrowicz A., Polkey M., Wilkinson M. Ursodeoxycholic acid for the treatment of flucloxacillin-associated cholestasis. J Hepatol 1995, 2:119-120.
60. Eckstein R.P., Dowsett J.F., Lunzer M.R. Flucloxacillin induced liver disease. Histopathological findings at biopsy and autopsy. Pathology 1993, 25:223-228.
61. Miros M., Kerlin P., Walker N., Harris O. Flucloxacillin induced delayed cholestatic hepatitis. Aust N Z J Med 1990, 20:251-253.
62. Koek G.H., Stricker B.H., Blok A.P., Schalm S.W., Desmet V.J. Flucloxacillin-associated hepatic injury. Liver 1994, 14:225-229.
63. Jick H., Derby L.E., Dean A.D., Henry D.A. Flucloxacillin and cholestatic hepatitis. Med J Aust 1994, 160:525.
64. Derby L.E., Jick H., Henry D.A., Dean A.D. Cholestatic hepatitis associated with flucloxacillin. Med J Aust 1993, 158:596-600.
65. George D.K., Crawford D.H. Antibacterial-induced hepatotoxicity. Incidence, prevention and management. Drug Saf 1996, 15:79-85.
66. Russmann S., Kaye J.A., Jick S.S., Jick H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK general practice research database. Br J Clin Pharmacol 2005, 60:76-82.
67. Lakehal F., Dansette P.M., Becquemont L., Lasnier E., Delelo R., Balladur P., et al. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol 2001, 14:694-701.
68. Carey M.A., van Pelt F.N. Immunochemical detection of flucloxacillin adduct formation in livers of treated rats. Toxicology 2005, 216:41-48.
69. Daly A.K., Donaldson P.T., Bhatnagar P., Pe'er S.Y., Floratos A., Daly M.J., DILIGEN Study, et al. HLA-B5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816-819.
70. Andrews E., Armstrong M., Tugwood J., Swan D., Glaves P., Pirmohamed M., et al. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 2010, 51:1656-1664.
71. Dowsett J.F., Gillow T., Heagerty A., Radcliffe M., Toadi R., Isle I., et al. Amoxicillin/clavulanic acid (Augmentin)-induced intrahepatic cholestasis. Dig Dis Sci 1989, 34:1290-1293.
72. Stricker B.H., Van den Broek J.W., Keuning J., Eberhardt W., Houben H.G., Johnson M., et al. Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (Augmentin). Dig Dis Sci 1989, 34:1576-1580.
73. Reddy K.R., Brillant P., Schiff E.R. Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology 1989, 96:1135-1141.
74. Schneider J.E., Kleinman M.S., Kupiec J.W. Cholestatic hepatitis after therapy with amoxicillin/clavulanate potassium. N Y State J Med 1989, 89:355-356.
75. Verhamme M., Ramboer C., Van de Bruaene P., Inderadjaja N. Cholestatic hepatitis due to an amoxicillin/clavulanic acid preparation. J Hepatol 1989, 9:260-264.
76. Silvain C., Fort E., Levillian P., Labat-Labourdette J., Beauchant M. Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid. Dig Dis Sci 1992, 37:150-152.
77. Larrey D., Vial T., Micaleff A., Babany G., Morichau-Beauchant M., Michel H., et al. Hepatitis associated with amoxicillin-clavulanic acid combination report of 15 cases. Gut 1992, 33:368-371.
78. Thomson J.A., Fairley C.K., Ugoni A.M., Forbes A.B., Purcell P.M., Desmond P.V., et al. Risk factors for the development of amoxicillin-clavulanic acid associated jaundice. Med J Aust 1995, 162:638-640.
79. Lucena M.I., Andrade R.J., Fernández M.C., Pachkoria K., Pelaez G., Durán J.A., et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006, 44:850-856.
80. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects-review of the literature. Eur J Med Res 2001, 6(4):139-149.
81. Ryley N.G., Fleming K.A., Chapman R.W. Focal destructive cholangiopathy associated with amoxycillin/clavulanic acid (Augmentin). J Hepatol 1995, 23:278-282.
82. Richardet J.P., Mallat A., Zafrani E.S., Blazquez M., Bognel J.C., Campillo B. Prolonged cholestasis with ductopenia after administration of amoxicillin/clavulanic acid. Dig Dis Sci 1999, 44:1997-2000.
83. Hebbard G.S., Smith K.G., Gibson P.R., Bhathal P.S. Augmentin-induced jaundice with a fatal outcome. Med J Aust 1992, 156:285-286.
84. Fontana R.J., Shakil A.O., Greenson J.K., Boyd I., Lee W.M. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci 2005, 50:1785-1790.
85. Chawla A., Kahn E., Yunis E.J., Daum F. Rapidly progressive cholestasis. An unusual reaction to amoxicillin/clavulanic acid therapy in a child. J Pediatr 2000, 136:121-123.
86. Smith L.A., Ignacio J.R., Winesett M.P., Kaiser G.C., Lacson A.G., Gilbert-Barness E., et al. Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 2005, 41:469-473.
87. Katsinelos P., Vasiliadis T., Xiarchos P., Patakiouta F., Christodoulou K., Pilpilidis I., et al. Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases. Eur J Gastroenterol Hepatol 2000, 12:365-368.
88. Hautekeete M.L., Horsmans Y., Van Waeyenberge C., Demanet C., Henrion J., Verbist L., et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999, 117:1181-1186.
89. O'Donohue J., Oien K.A., Donaldson P., Underhill J., Clare M., MacSween R.N., et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000, 47:717-720.
90. Donaldson P.T., Daly A.K., Henderson J., Graham J., Pirmohamed M., Bernal W., et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010, 53:1049-1053.
91. Lucena M.I., Molokhia M., Shen Y., Urban T.J., Aithal G.P., Andrade R.J., Spanish DILI Registry, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141:338-347.
92. Berg P., Hahn E.G. Hepatotoxic reactions induced by beta-lactamase inhibitors. Eur J Med Res 2001, 6:535-542.
93. Parry M.F. The safety and tolerance of azlocillin. Arzneimittelforschung 1985, 35:1292-1294.
94. Lang R., Lishner M., Ravid M. Adverse reactions to prolonged treatment with high doses of carbenicillin and ureidopenicillins. Rev Infect Dis 1991, 13:68-72.
95. Hargreaves J.E., Herchline T.E. Severe cholestatic jaundice caused by mezlocillin. Clin Infect Dis 1992, 15:179-180.
96. Quattropani C., Schneider M., Helbling A., Zimmermann A., Krahenbuhl S. Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin. Liver 2001, 21:213-216.
97. Schumaker A.L., Okulicz J.F. Meropenem-induced vanishing bile duct syndrome. Pharmacotherapy 2010, 30:953.
98. Ammann R., Neftel K., Hardmeier T., Reinhardt M. Cephalosporin-induced cholestatic jaundice. Lancet 1982, 2:336-337.
99. Eggleston S.M., Belandres M.M. Jaundice associated with cephalosporin therapy. Drug Intell Clin Pharm 1985, 19:553-555.
100. Bjornsson E., Olsson R. Acute liver injury due to loracarbef. J Hepatol 1997, 26:739-740.
101. Skoog S.M., Smyrk T.C., Talwalkar J.A. Cephalexin-induced cholestatic hepatitis. J Clin Gastroenterol 2004, 38:833.
102. Shiffman M.L., Keith F.B., Moore E.W. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990, 99:1772-1778.
103. Peker E., Cagan E., Dogan M. Ceftriaxone-induced toxic hepatitis. World J Gastroenterol 2009, 15:2669-2671.
104. Johnson D.F., Hall W.H. Allergic hepatitis caused by propionyl erythromycin ester of lauryl sulfate. N Engl J Med 1961, 265:1200-1202.
105. Reed C., Ritchie F. Toxic jaundice due to propionyl erythromycin ester lauryl sulphate ("Ilosone"). Med J Aust 1962, 49:810-812.
106. Tolman K.G., Sannella J.J., Freston J.W. Chemical structure of erythromycin and hepatotoxicity. Ann Intern Med 1974, 81:58-60.
107. Zafrani E.S., Ishak K.G., Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci 1979, 24:385-396.
108. Viteri A.L., Greene J.F., Dyck W.P. Erythromycin ethylsuccinate-induced cholestasis. Gastroenterology 1979, 76:1007-1008.
109. Keeffe E.B., Reis T.C., Berland J.E. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate. Dig Dis Sci 1982, 27:701-704.
110. Diehl A.M., Latham P., Boitnott J.K., Mann J., Maddrey W.C. Cholestatic hepatitis from erythromycin ethylsuccinate. Report of two cases. Am J Med 1984, 76:931-934.
111. Inman W.H., Rawson N.S. Erythromycin estolate and jaundice. Br Med J 1983, 286:1954-1955.
112. Avila P., Capella D., Laporte J.R., Moreno V. Which salt of erythromycin is most hepatotoxic?. Lancet 1988, 1:1104.
113. Derby L.E., Jick H., Henry D.A., Dean A.D. Erythromycin-associated cholestatic hepatitis. Med J Aust 1993, 158:600-602.
114. Geubel A.P., Nakad A., Rahier J., Dive C. Prolonged cholestasis and disappearance of interlobular bile ducts following chlorpropamide and erythromycin ethylsuccinate. Case of drug interaction?. Liver 1988, 8:350-353.
115. Degott C., Feldmann G., Larrey D., Durand-Schneider A.M., Grange D., Machayekhi J.P., et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992, 15:244-251.
116. Lazarczyk D.A., Duffy M.C. Erythromycin-induced primary biliary cirrhosis. Dig Dis Sci 2000, 45:1115-1118.
117. Gholson C.F., Warren G.H. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med 1990, 150:215-216.
118. Longo G., Valenti C., Gandini G., Ferrara L., Bertesi M., Emilia G. Azithromycin-induced intrahepatic cholestasis. Am J Med 1997, 102:217-218.
119. Cascaval R.I., Lancaster D.J. Hypersensitivity syndrome associated with azithromycin. Am J Med 2001, 110:330-331.
120. Chandrupatla S., Demetris A.J., Rabinovitz M. Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci 2002, 47:2186-2188.
121. Molleston J.P., Fontana R.J., Lopez M.J., Kleiner D.E., Gu J., Chalasani N., for the Drug-Induced Liver Injury Network, et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr 2011, 53:182-189.
122. Sturgill M.G., Rapp R.P. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother 1992, 26:1099-1108.
123. Yew W.W., Chau C.H., Lee J., Leung C.W. Cholestatic hepatitis in a patient who received clarithromycin therapy for a Mycobacterium chelonae lung infection. Clin Infect Dis 1994, 18:1025-1026.
124. Brown B.A., Wallace R.J., Griffith D.E., Girard W. Clarithromycin-induced hepatotoxicity. Clin Infect Dis 1995, 20:1073-1074.
125. Fox J.C., Szyjkowski R.S., Sanderson S.O., Levine R.A. Progressive cholestatic liver disease associated with clarithromycin treatment. J Clin Pharmacol 2002, 42:676-680.
126. Shaheen N., Grimm I.S. Fulminant hepatic failure associated with clarithromycin. Am J Gastroenterol 1996, 91:394-395.
127. Masia M., Gutierrez F., Jimeno A., Navarro A., Borras J., Matarredona J., et al. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy. Arch Intern Med 2002, 162:474-476.
128. Christopher K., Hyatt P.A., Horkan C., Yodice P.C. Clarithromycin use preceding fulminant hepatic failure. Am J Gastroenterol 2002, 97:489-490.
129. Tietz A., Heim M.H., Eriksson U., Marsch S., Terracciano L., Krahenbuhl S. Fulminant liver failure associated with clarithromycin. Ann Pharmacother 2003, 37:57-60.
130. Nguyen M., Chung E.P. Telithromycin: the first ketolide antimicrobial. Clin Ther 2005, 27:1144-1163.
131. Peters T.S. Do preclinical testing strategies help predict human hepatotoxic potentials?. Toxicol Pathol 2005, 33:146-154.
132. Clay K.D., Hanson J.S., Pope S.D., Rissmiller R.W., Purdum P.P., Banks P.M. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006, 144:415-420.
133. Brinker A.D., Wassel R.T., Lyndly J., Serrano J., Avigan M., Lee W.M., et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009, 49:250-257.
134. Yamaguchi S., Zhao Y.L., Nadai M., Yoshizumi H., Cen X., Torita S., et al. Involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother 2006, 50:80-87.
135. Gaeta G.B., Utili R., Adinolfi L.E., Abernathy C.O., Giusti G. Characterization of the effects of erythromycin estolate and erythromycin base on the excretory function of the isolated rat liver. Toxicol Appl Pharmacol 1985, 80:185-192.
136. Kostrubsky V.E., Strom S.C., Hanson J., Urda E., Rose K., Burliegh J., et al. Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci 2003, 76:220-228.
137. Ansede J.H., Smith W.R., Perry C.H., Claire R.L., Brouwer K.R. An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes. Drug Metab Dispos 2010, 38:276-280.
138. Pessayre D., Larrey D., Funck-Brentano C., Benhamou J.P. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 1985, 16(Suppl. A):181-194.
139. Westphal J.F., Brogard J.M. Antibacterials and antifungal agents. Drug-induced liver disesase 2003, 471-504. Marcel Dekker, New York. N. Kaplowitz, L.D. DeLeve (Eds.).
140. Dujovne C.A., Chan C.H., Zimmerman H.J. Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med 1967, 277:785-788.
141. Gordin F.M., Simon G.L., Wofsy C.B., Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984, 100:495-499.
142. Espiritu C.R., Kim T.S., Levine R.A. Granulomatous hepatitis associated with sulfadimethoxine hypersensitivity. JAMA 1967, 202:985-988.
143. Callen J.P., Soderstrom R.M. Granulomatous hepatitis associated with salicylazosulfapyridine therapy. South Med J 1978, 71:1159-1160.
144. Lazar H.P., Murphy R.L., Phair J.P. Fansidar and hepatic granulomas. Ann Intern Med 1985, 102:722.
145. Zaman F., Ye G., Abreo K.D., Latif S., Zibari G.B. Successful orthotopic liver transplantation after trimethoprim-sulfamethoxazole associated fulminant liver failure. Clin Transplant 2003, 17:461-464.
146. Alberti-Flor J.J., Hernandez M.E., Ferrer J.P., Howell S., Jeffers L. Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim. Am J Gastroenterol 1989, 84:1577-1579.
147. Zitelli B.J., Alexander J., Taylor S., Miller K.D., Howrie D.L., Kuritsky J.N., et al. Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). Ann Intern Med 1987, 106:393-395.
148. Ransohoff D.F., Jacobs G. Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim. Gastroenterology 1981, 80:816-819.
149. Yao F., Behling C.A., Saab S., Li S., Hart M., Lyche K.D. Trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol 1997, 92:167-169.
150. Altraif I., Lilly L., Wanless I.R., Heathcote J. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole. Am J Gastroenterol 1994, 89:1230-1234.
151. Kowdley K.V., Keeffe E.B., Fawaz K.A. Prolonged cholestasis due to trimethoprim sulfamethoxazole. Gastroenterology 1992, 102:2148-2150.
152. Abi-Mansur P., Ardiaca M.C., Allam C., Shamma'a M. Trimethoprim-sulfamethoxazole-induced cholestasis. Am J Gastroenterol 1981, 76:356-359.
153. Nair S.S., Kaplan J.M., Levine L.H., Geraci K. Trimethoprim-sulfamethoxazole-induced intrahepatic cholestasis. Ann Intern Med 1980, 92:511-512.
154. Munoz S.J., Martinez-Hernandez A., Maddrey W.C. Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim-sulfamethoxazole. Hepatology 1990, 12:342-347.
155. Thies P.W., Dull W.L. Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis: inadvertent rechallenge. Arch Intern Med 1984, 144:1691-1692.
156. Wolkenstein P., Carriere V., Charue D., Bastuji-Garin S., Revuz J., Roujeau J.C., et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995, 5:255-258.
157. O'Neil W.M., MacArthur R.D., Farrough M.J., Doll M.A., Fretland A.J., Hein D.W., et al. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J Clin Pharmacol 2002, 42:613-619.
158. Alfirevic A., Stalford A.C., Vilar F.J., Wilkins E.G., Park B.K., Pirmohamed M. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol 2003, 55:158-165.
159. Dowling H.F., Lepper M.H. Hepatic reactions to tetracycline. JAMA 1964, 188:307-309.
160. Zimmerman H.J. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver 1999, Lippincott Williams & Wilkins, Philadelphia. 2nd ed.
161. Combes B., Whalley P.J., Adams R.H. Tetracycline and the liver. Prog Liver Dis 1972, 4:589-596.
162. Whalley P.J., Adams R.H., Combes B. Tetracycline toxicity in pregnancy. JAMA 1964, 189:357-362.
163. Allen E.S., Brown W.E. Hepatic toxicity of tetracycline in pregnancy. Am J Obstet Gynecol 1966, 95:12-18.
164. Schultz J.C., Adamson J.S., Workman W.W., Norman T.D. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 1963, 269:999-1004.
165. Freneaux E., Labbe G., Letteron P., Le Dinh T., Degott C., Geneve J., et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988, 8:1056-1062.
166. Letteron P., Sutton A., Mansouri A., Fromenty B., Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003, 38:133-140.
167. Bjornsson E., Lindberg J., Olsson R. Liver reactions to oral low-dose tetracyclines. Scand J Gastroenterol 1997, 32:390-395.
168. Hunt C.M., Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 1994, 107:1844-1847.
169. Westermann G.W., Bohm M., Bonsmann G., Rahn K.H., Kisters K. Chronic intoxication by doxycycline use for more than 12 years. J Intern Med 1999, 246(6):591-592.
170. Burette A., Finet C., Prigogine T., De Roy G., Deltenre M. Acute hepatic injury associated with minocycline. Arch Intern Med 1984, 144:1491-1492.
171. Davies M.G., Kersey P.J. Acute hepatitis and exfoliative dermatitis associated with minocycline. Br Med J 1989, 298:1523-1524.
172. Malcolm A., Heap T.R., Eckstein R.P., Lunzer M.R. Minocycline-induced liver injury. Am J Gastroenterol 1996, 91:1641-1643.
173. Gough A., Chapman S., Wagstaff K., Emery P., Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. Br Med J 1996, 312:169-172.
174. Teitelbaum J.E., Perez-Atayde A.R., Cohen M., Bousvaros A., Jonas M.M. Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med 1998, 152:1132-1136.
175. Crosson J., Stillman M.T. Minocycline-related lupus erythematosus with associated liver disease. J Am Acad Dermatol 1997, 36:867-868.
176. Golstein P.E., Deviere J., Cremer M. Acute hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol 1997, 92:143-146.
177. Bhat G., Jordan J., Sokalski S., Bajaj V., Marshall R., Berkelhammer C. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol 1998, 27:74-75.
178. Goldstein N.S., Bayati N., Silverman A.L., Gordon S.C. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 2000, 114:591-598.
179. Nietsch H.H., Libman B.S., Pansze T.W., Eicher J.N., Reeves J.R., Krawitt E.L. Minocycline-induced hepatitis. Am J Gastroenterol 2000, 95:2993-2995.
180. Min D.I., Burke P.A., Lewis W.D., Jenkins R.L. Acute hepatic failure associated with oral minocycline: a case report. Pharmacotherapy 1992, 12:68-71.
181. Boudreaux J.P., Hayes D.H., Mizrahi S., Hussey J., Regenstein F., Balart L. Fulminant hepatic failure, hepatorenal syndrome, and necrotizing pancreatitis after minocycline hepatotoxicity. Transplant Proc 1993, 25:1873.
182. Pohle T., Menzel J., Domschke W. Minocycline and fulminant hepatic failure necessitating liver transplantation. Am J Gastroenterol 2000, 95:560-561.
183. Lawrenson R.A., Seaman H.E., Sundstrom A., Williams T.J., Farmer R.D. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf 2000, 23:333-349.
184. Maddrey W.C. Drug-induced hepatotoxicity. J Clin Gastroenterol 2005, 39(Suppl. 2):S83-S89.
185. Kaufmann D., Pichler W., Beer J.H. Severe episode of high fever with rash, lymphadenopathy, neutropenia, and eosinophilia after minocycline therapy for acne. Arch Intern Med 1994, 154:1983-1984.
186. Seaman H.E., Lawrenson R.A., Williams T.J., MacRae K.D., Farmer R.D. The risk of liver damage associated with minocycline: a comparative study. J Clin Pharmacol 2001, 41:852-860.
187. Liu Z.X., Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002, 6:755-774.
188. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(Suppl. 5):S354-S367. Tigecycline 301 Study Group, Tigecycline 306 Study Group.
189. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl. 5):S341-S353. Tigecycline 300 cSSSI Study Group.
190. Owens R.C., Ambrose P.G. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005, 41(Suppl. 2):S144-S157.
191. Lopez-Navidad A., Domingo P., Cadafalch J., Farrerons J. Norfloxacin-induced hepatotoxicity. J Hepatol 1990, 11:277-278.
192. Blum A. Ofloxacin-induced acute severe hepatitis. South Med J 1991, 84:1158.
193. Villeneuve J.P., Davies C., Cote J. Suspected ciprofloxacin-induced hepatotoxicity. Ann Pharmacother 1995, 29:257-259.
194. Sherman O., Beizer J.L. Possible ciprofloxacin induced cholestatic jaundice. Ann Pharmacother 1994, 28:1162-1164.
195. Hautekeete M.L. Cholestatic hepatitis related to quinolones: a report of two cases. J Hepatol 1995, 23:759-760.
196. Labowitz J.K., Silverman W.B. Cholestatic jaundice induced by ciprofloxacin. Dig Dis Sci 1997, 142:192-194.
197. Lucena M.I., Andrade R.J., Sanchez-Martinez H., Perez-Serrano J.M., Gomez-Outes A. Norfloxacin-induced cholestatic jaundice. Am J Gastroenterol 1998, 93:2309-2311.
198. Soto S., Lopez-Roses L., Avila S., Lancho A., Gonzalez A., Santos E., et al. Moxifloxacin-induced acute liver injury. Am J Gastroenterol 2002, 97:1853-1854.
199. Bataille L., Rahier J., Geubel A. Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease. J Hepatol 2002, 37:696-699.
200. Cheung O., Chopra K., Yu T., Nalesnik M.A., Amin S., Shakil A.O. Gatifloxacin-induced hepatotoxicity and acute pancreatitis. Ann Intern Med 2004, 140:73-74.
201. Grassmick B.K., Lehr V.T., Sundareson A.S. Fulminant hepatic failure possibly related to ciprofloxacin. Ann Pharmacother 1992, 26:636-639.
202. Fuchs S., Simon Z., Brezin M. Fatal hepatic failure associated with ciprofloxacin. Lancet 1994, 343:738-739.
203. Coleman C.I., Spencer J.V., Chung J.O., Reddy P. Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother 2002, 36:1162-1167.
204. Zimpfer A., Propst A., Mikuz G., Vogel W., Terracciano L., Stadlmann S. Ciprofloxacin-induced acute liver injury: case report and review of literature. Virchows Arch 2004, 444:87-89.
205. Orman E.S., Conjeevaram H.S., Vuppalanchi R., Freston J.W., Rochon J., Kleiner D.E., DILIN Research Group, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011, 9:517-523.
206. Lucena M.I., Andrade R.J., Rodrigo L., Salmeron J., Alvarez A., Lopez-Garrido M.J., et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis 2000, 30:400-401.
207. Chen H.J., Bloch K.J., Maclean J.A. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med 2000, 342:359-360.
208. Lazarczyk D.A., Goldstein N.S., Gordon S.C. Trovafloxacin hepatotoxicity. Dig Dis Sci 2001, 46:925-926.
209. Bertino J., Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000, 22:798-817.
210. Liguori M.J., Anderson L.M., Bukofzer S., McKim J., Pregenzer J.F., Retief J., et al. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 2005, 41:177-186.
211. Buchweitz J.P., Ganey P.E., Bursian S.J., Roth R.A. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy?. J Pharmacol Exp Ther 2002, 300:460-467.
212. Roth R.A., Luyendyk J.P., Maddox J.F., Ganey P.E. Inflammation and drug idiosyncrasy-is there a connection?. J Pharmacol Exp Ther 2003, 307:1-8.
213. Ganey P.E., Luyendyk J.P., Maddox J.F., Roth R.A. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 2004, 150:35-51.
214. Waring J.F., Liguori M.J., Luyendyk J.P., Maddox J.F., Ganey P.E., Stachlewitz R.F., et al. Microarray analysis of LPS potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 2006, 316:1080-1087.
215. Shaw P.J., Ganey P.E., Roth R.A. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 2010, 118:7.
216. Cadle R.M., Mansouri M.D., Darouiche R.O. Vancomycin-induced elevation of liver enzyme levels. Ann Pharmacother 2006, 40:1186-1189.
217. Chen Y., Hornbuckle K., Killian C., Regev A., Voss S., Yang X.Y. Risks of hepatic events in patients treated with vancomycin in clinical studies: a systematic review and meta-analysis. Drug Saf 2011, 34:73-82.
218. D'Arcy P.F. Nitrofurantoin. Drug Intell Clin Pharm 1985, 19:540-547.
219. Goldstein L.I., Ishak K.G., Burns W. Hepatic injury associated with nitrofurantoin therapy. Am J Dig Dis 1974, 19:987-998.
220. Sharp J.R., Ishak K.G., Zimmerman H.J. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980, 92:14-19.
221. Black M., Rabin L., Schatz N. Nitrofurantoin-induced chronic active hepatitis. Ann Intern Med 1980, 92:62-64.
222. Sippel P.J., Agger W.A. Nitrofurantoin-induced granulomatous hepatitis. Urology 1981, 18:177-178.
223. Stricker B.H., Blok A.P., Claas F.H., Van Parys G.E., Desmet V.J. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988, 8:599-606.
224. Klemola H., Penttila O., Runeberg L., Tallqvist G. Anicteric liver damage during nitrofurantoin medication. Scand J Gastroenterol 1975, 10:501-505.
225. Fagrell B., Strandberg I., Wengle B. A nitrofurantoin-induced disorder simulating chronic active hepatitis. A case report. Acta Med Scand 1976, 199:237-239.
226. Appleyard S., Gorard D.A., Saraswati R. Autoimmune hepatitis triggered by nitrofurantoin: a case series. J Med Case Reports 2010, 4:311.
227. Peedikayil M.C., Dahhan T.I., Al Ashgar H.I. Nitrofurantoin-induced fulminant hepatitis mimicking autoimmune hepatitis. Ann Pharmacother 2006, 40:1888-1889.
228. Stromberg A., Wengle B. Chronic active hepatitis induced by nitrofurantoin. Br Med J 1976, 2:174-175.
229. Iwarson S., Lindberg J., Lundin P. Nitrofurantoin-induced chronic liver disease. Clinical course and outcome of five cases. Scand J Gastroenterol 1979, 14:497-502.
230. Holmberg L., Boman G., Bottiger L.E., Eriksson B., Spross R., Wessling A. Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med 1980, 69:733-738.
231. Paiva L.A., Wright P.J., Koff R.S. Long-term hepatic memory for hypersensitivity to nitrofurantoin. Am J Gastroenterol 1992, 87:891-893.
232. Engel J.J., Vogt T.R., Wilson D.E. Cholestatic hepatitis after administration of furan derivatives. Arch Intern Med 1975, 135:733-735.
233. Merino G., Jonker J.W., Wagenaar E., van Herwaarden A.E., Schinkel A.H. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 2005, 67:1758-1764.
234. Merino G., van Herwaarden A.E., Wagenaar E., Jonker J.W., Schinkel A.H. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol 2005, 67:1765-1771.
235. Vavricka S.R., Van Montfoort J., Ha H.R., Meier P.J., Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002, 36:164-172.
236. Tirona R.G., Leake B.F., Wolkoff A.W., Kim R.B. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003, 304:223-228.
237. Acocella G., Nicolis F.B., Tenconi L.T. The effect of an intravenous infusion of rifamycin SV on the excretion of bilirubin, bromsulphalein and indocyanine green in man. Gastroenterology 1965, 49:521-525.
238. Galeazzi R., Lorenzini I., Orlandi F. Rifampicin-induced elevation of serum bile acids in man. Dig Dis Sci 1980, 25:108-112.
239. Marschall H.U., Wagner M., Zollner G., Fickert P., Diczfalusy U., Gumhold J., et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005, 129:476-485.
240. Prince M.I., Burt A.D., Jones D.E. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002, 50:436-439.
241. Elmore M., Rissing J.P., Rink L., Brooks G.F. Clindamycin-associated hepatotoxicity. Am J Med 1974, 57:627-630.
242. Aygun C., Kocaman O., Gurbuz Y., Senturk O., Hulagu S. Clindamycin-induced acute cholestatic hepatitis. World J Gastroenterol 2007, 13:5408-5410.
243. Arbeit R.D., Maki D., Tally F.P., Campanaro E., Eisenstein B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673-1681. Daptomycin 98-01 and 99-01 Investigators.
244. Echevarria K., Datta P., Cadena J., Lewis J.S. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 2005, 55:599-600.
245. Abraham G., Finkelberg D., Spooner L.M. Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis. Ann Pharmacother 2008, 42:719-721.
246. Stevens D.L., Dotter B., Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004, 2:51-59.
247. De Bus L., Depuydt P., Libbrecht L., Vandekerckhove L., Nollet J., Benoit D., et al. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol 2010, 6(3):322-326.
248. De Vriese A.S., Van Coster R., Smet J., Seneca S., Lovering A., Van Haute L.L., et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006, 42:1111-1117.
249. Ikuta S.-I., Tanimura K., Yasui C., Aihara T., Yoshie H., Iida H., et al. Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery. J Infect Chemother 2011, 17:388-391.
250. Rubinstein E., Prokocimer P., Talbot G.H. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999, 44:37-46.
251. Linden P.K., Bompart F., Gray S., Talbot G.H. Hyperbilirubinemia during quinupristin-dalfopristin therapy in liver transplant recipients: correlation with available liver biopsy results. Pharmacotherapy 2001, 21:661-668.
252. Carnecchia B.M., Kurtzke J.F. Fatal toxic reaction to amphotericin B in cryptococcal meningo-encephalitis. Ann Intern Med 1960, 53:1027-1036.
253. Miller M.A. Reversible hepatotoxicity related to amphotericin B. Can Med Assoc J 1984, 131:1245-1247.
254. Gill J., Sprenger H.R., Ralph E.D., Sharpe M.D. Hepatotoxicity possibly caused by amphotericin B. Ann Pharmacother 1999, 33:683-685.
255. Meunier F., Prentice H.G., Ringden O. Liposomal amphotericin B [AmBisome]: safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991, 28(Suppl. B):83-91.
256. Ellis M., Shamoon A., Gorka W., Zwaan F., al-Ramadi B. Severe hepatic injury associated with lipid formulations of amphotericin B. Clin Infect Dis 2001, 32:E87-E89.
257. Fischer M.A., Winkelmayer W.C., Rubin R.H., Avorn J. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005, 41:301-307.
258. Wingard J.R., Leather H. Hepatotoxicity associated with antifungal therapy after bone marrow transplantation. Clin Infect Dis 2005, 41:308-310.
259. Patel G.P., Crank C.W., Leikin J.B. An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB). J Med Toxicol 2011, 7:12-15.
260. Chamilos G., Luna M., Lewis R.E., Raad C.R., Kontoyiannis D.P. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clin Ther 2007, 29:1980-1986.
261. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., Caspofungin Invasive Candidiasis Study Group, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029.
262. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., Caspofungin Salvage Aspergillosis Study Group, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39:1563-1571.
263. Bennett J.E. Echinocandins for candidemia in adults with neutropenia. N Engl J Med 2006, 355:1154-1159.
264. Christopeit M., Eikam M., Behre G. Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity. Mycoses 2008, 51(Suppl. 1):19-24.
265. Cappelletty D., Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007, 27:369-388.
266. Garcia Rodriguez L.A., Duque A., Castellsague J., Perez-Gutthann S., Stricker B.H. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999, 48:847-852.
267. Bradbury B.D., Jick S.S. Itraconazole and fluconazole and certain rare, serious adverse events. Pharmacotherapy 2002, 22:697-700.
268. Stricker B.H., Blok A.P., Bronkhorst F.B., Van Parys G.E., Desmet V.J. Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases. J Hepatol 1986, 3:399-406.
269. Janssen P.A., Symoens J.E. Hepatic reactions during ketoconazole treatment. Am J Med 1983, 74:80-85.
270. Chien R.N., Yang L.J., Lin P.Y., Liaw Y.F. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 1997, 25:103-107.
271. Lewis J.H., Zimmerman H.J., Benson G.D., Ishak K.G. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 1984, 86:503-513.
272. Duarte P.A., Chow C.C., Simmons F., Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med 1984, 144:1069-1070.
273. Bercoff E., Bernuau J., Degott C., Kalis B., Lemaire A., Tilly H., et al. Ketoconazole-induced fulminant hepatitis. Gut 1985, 26:636-638.
274. Lake-Bakaar G., Scheuer P.J., Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J 1987, 294:419-422.
275. Kim T.-H., Kim B.-H., Kim Y.-W., Yang D.M., Han Y.S., Dong S.H., et al. Liver cirrhosis developed after ketoconazole-induced acute hepatic injury. J Gastroenterol Hepatol 2003, 18:1426-1429.
276. Como J.A., Dismukes W.E. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994, 330:263-272.
277. Munoz P., Moreno S., Berenguer J., Bernaldo de Quiros J.C.L., Bouza E. Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome. Arch Intern Med 1991, 151:1020-1021.
278. Franklin I.M., Elias E., Hirsch C. Fluconazole-induced jaundice. Lancet 1990, 336:565.
279. Wells C., Lever A.M. Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge. J Infect 1992, 24:111-112.
280. Jacobson M.A., Hanks D.K., Ferrel L.D. Fatal acute hepatic necrosis due to fluconazole. Am J Med 1994, 96:188-190.
281. Trujillo M.A., Galgiani J.N., Sampliner R.E. Evaluation of hepatic injury arising during fluconazole therapy. Arch Intern Med 1994, 154:102-104.
282. Gearhart M.O. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother 1994, 28:1177-1181.
283. Bronstein J.A., Gros P., Hernandez E., Larroque P., Molinie C. Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clin Infect Dis 1997, 25:1266-1267.
284. Schottker B., Dosch A., Kraemer D.M. Severe hepatotoxicity after application of desloratadine and fluconazole. Acta Haematol 2003, 110:43-44.
285. Guillaume M.P., De Prez C., Cogan E. Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration. Am J Gastroenterol 1996, 91:165-168.
286. Tucker R.M., Haq Y., Denning D.W., Stevens D.A. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990, 26:561-566.
287. Hay R.J. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993, 29:S50-S54.
288. Lavrijsen A.P., Balmus K.J., Nugteren-Huying W.M., Roldaan A.C., van't Wout J.W., Stricker B.H. Hepatic injury associated with itraconazole. Lancet 1992, 340:251-252.
289. Gallardo-Quesada S., Luelmo-Aguilar J., Guanyabens-Calvet C. Hepatotoxicity associated with itraconazole. Int J Dermatol 1995, 34:589.
290. Adriaenssens B., Roskams T., Steger P., Van Steenbergen W. Hepatotoxicity related to itraconazole: report of three cases. Acta Clin Belg 2001, 56:364-369.
291. Gupta A.K., Chwetzoff E., Del Rosso J., Baran R. Hepatic safety of itraconazole. J Cutan Med Surg 2002, 6:210-213.
292. Tuccori M., Bresci F., Guidi B., Blandizzi C., Del Tacca M., Di Paolo M. Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis. Ann Pharmacother 2008, 42:1112-1117.
293. Yoshikado T., Takada T., Yamamoto T., Yamaji H., Ito K., Santa T., et al. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol Pharmacol 2011, 79:241-245.
294. Potoski B.A., Brown J. The safety of voriconazole. Clin Infect Dis 2002, 35:1273-1275.
295. Johnson L.B., Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003, 36:630-637.
296. Spellberg B., Rieg G., Bayer A., Edwards J.E. Lack of cross-hepatotoxicity between fluconazole and voriconazole. Clin Infect Dis 2003, 36:1091-1093.
297. Foo H., Gottlieb T. Lack of cross-hepatoxicity between voriconazole and posaconazole. Clin Infect Dis 2007, 45:803-805.
298. Hall M., Monka C., Krupp P., O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol 1997, 133:1213-1219.
299. Zapata Garrido A.J., Romo A.C., Padilla F.B. Terbinafine hepatotoxicity. A case report and review of literature. Ann Hepatol 2003, 2:47-51.
300. Fernandes N.F., Geller S.A., Fong T.L. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol 1998, 93:459-460.
301. Gupta A.K., del Rosso J.Q., Lynde C.W., Brown G.H., Shear N.H. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol 1998, 23:64-67.
302. Lazaros G.A., Papatheodoridis G.V., Delladetsima J.K., Tassopoulos N.C. Terbinafine-induced cholestatic liver disease. J Hepatol 1996, 24:753-756.
303. Van't Wout J.W., Herrmann W.A., de Vries R.A., Stricker B.H. Terbinafine-associated hepatic injury. J Hepatol 1994, 21:115-117.
304. Lowe G., Green C., Jennings P. Hepatitis associated with terbinafine treatment. Br Med J 1993, 306:248.
305. Chang C.-H., Young-Xu Y., Kurth T., Orav J.E., Chan A.K. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med 2007, 120:791-798.
306. Agarwal K., Manas D.M., Hudson M. Terbinafine and fulminant hepatic failure. N Engl J Med 1999, 340:1292-1293.
307. Perveze Z., Johnson M.W., Rubin R.A., Sellers M., Zayas C., Jones J.L., et al. Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl 2007, 13:162-164.
308. Mallat A., Zafrani E.S., Metreau J.M., Dhumeaux D. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci 1997, 42:1486-1488.
309. Anania F.A., Rabin L. Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am J Med 2002, 112:741-742.
310. Paredes A.H., Lewis J.H. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother 2007, 41:880-884.
311. Ajit C., Suvannasankha A., Zaeri N., Munoz S.J. Terbinafine-associated hepatotoxicity. Am J Med Sci 2003, 325:292-295.
312. Vermes A., Guchelaar H.J., Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000, 46:171-179.
313. Record C.O., Skinner J.M., Sleight P., Speller D.C. Candida endocarditis treated with 5-fluorocytosine. Br Med J 1971, 1:262-264.
314. Libbrecht L., Meerman L., Kuipers F., Roskams T., Desmet V., Jansem P. Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria. J Pathol 2003, 199:191-200.
315. Chiprut R.O., Viteri A., Jamroz C., Dyck W.P. Intrahepatic cholestasis after griseofulvin administration. Gastroenterology 1976, 70:1141-1143.
316. Berman A., Franklin R.L. Precipitation of acute intermittent porphyria by griseofulvin therapy. JAMA 1965, 192:1005-1007.